- Home
- BTMD
BTMD
Biote Corp.
as 11-11-2025 3:36pm EST
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | IRVING |
| Market Cap: | 90.6M | IPO Year: | N/A |
| Target Price: | $6.00 | AVG Volume (30 days): | 117.0K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.78 | EPS Growth: | 270.48 |
| 52 Week Low/High: | $2.43 - $6.98 | Next Earning Date: | 11-05-2025 |
| Revenue: | $195,645,000 | Revenue Growth: | 1.34% |
| Revenue Growth (this year): | -0.34% | Revenue Growth (next year): | 4.85% |
Latest Biote Corp. News
BTMD Breaking Stock News: Dive into BTMD Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 days ago
biote Corp. Just Beat EPS By 371%: Here's What Analysts Think Will Happen Next
Motley Fool
6 days ago
biote (BTMD) Q3 2025 Earnings Call Transcript
GuruFocus.com
6 days ago
Biote Corp (BTMD) Q3 2025 Earnings Call Highlights: Strategic Progress Amid Revenue Challenges
Zacks
6 days ago
biote Corp. (BTMD) Tops Q3 Earnings and Revenue Estimates
Business Wire
6 days ago
Biote Reports Third Quarter 2025 Financial Results
GuruFocus.com
8 days ago
Biote Corp (BTMD) Q3 2025 Earnings Report Preview: What To Expect
Business Wire
20 days ago
Biote Schedules Third Quarter 2025 Financial Results Release and Conference Call
Business Wire
5 months ago
Biote Names Rich Barrera to Board of Directors
Compare BTMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BTMD Biote Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.